Where can I buy Ensidipine?

Enasidenib is a targeted anti-cancer drug mainly used to treat a specific type of acute myeloid leukemia (AML). It works by inhibiting mutated isocitrate dehydrogenase 2 (IDH2), which is common in some AML patients.

Ensidipine is not currently available in the country, so patients cannot purchase it directly in the country and need to obtain it through overseas channels. Abroad, the more affordable option is generic drugs, especially those from Laos and Bangladesh. Their price is about 2,000 yuan, and their pharmaceutical ingredients are highly similar to original drugs.

Acute myeloid leukemia is a cancer that affects the white blood cells in the bone marrow, often causing bone marrow dysfunction that allows abnormal white blood cells to proliferate and interfere with the production of normal blood cells. IDH2mutation is a common type of mutation in AML that leads to abnormal metabolic pathways, thereby promoting the growth and survival of cancer cells. Ensidipine targets this mutation and restores the normal metabolic process of cells by inhibiting the mutated IDH2 enzyme and inducing the differentiation and apoptosis of cancer cells.

The efficacy of ensidipine has been demonstrated in multiple clinical trials. In a pivotal clinical trial, patients with AML harboring IDH2 mutations showed significant response rates when treated with ensidipine. The results of these trials show that ensidipine can not only prolong the progression-free survival of patients, but also improve the overall survival rate and significantly improve the prognosis of patients.

Ensidipine is usually given as an oral tablet once daily. Common side effects include nausea, vomiting, diarrhea, fatigue and loss of appetite. In addition, ensidipine may cause a serious complication called differentiation syndrome, an inflammatory response caused by rapid differentiation of cancer cells that requires prompt recognition and treatment.

As a targeted therapy, the application of ensidipine has greatly changed the treatment model for specific AML patients, providing treatment for those carrying IDH2Mutations provide an effective treatment option for patients. However, due to its limited scope of application, ensidipine is mainly targeted at patients with AML who are known to have IDH2 mutations, so genetic testing is required to confirm the presence of the mutation before use.